

Make Money In Up or Down Markets

A Publication of Princeton Research, Inc. (www.PrincetonResearch.com)

Contributing Staff: Charles Moskowitz Michael King

Charles Moskowitz Discussion

Week 34 was a solid gain of \$1,385 bringing YTD performance to another new high of \$12,458. Both trades started with a 100% Up Rule liquidation and followed with higher prices on the balance. One subscriber called and asked why we didn't wait and get bigger gains, and the answer is that the rules are the rules for a reason, and we follow them regardless of what we think of the trades. As Bernard Baruch said, "I made most of my money getting out too soon." We have 3 open positions, the second half of our SKYW (also a 100% Rule trade) with no actual cost, CSTM 9/10 calls @ \$.80, and I rolled up to next week's NVDA 170 calls for a total funds in use of \$1456.

Last week I closed with the following; With all these factors, you would think lower prices are coming, but my tactic is to take advantage of the closeness of the lows to be a buyer using the breakdowns as my stopping-out point. This will be the method for the week (or weeks) coming. It may cause some small losses, but even 1 or 2 that hold and start higher will make money. Watch for text alerts to participate. CAM

We bought the NVDA and M calls without much risk and we made outstanding gains on both with 100% up rule executions. This week's A.A.I.I. Sentiment numbers actually got more bearish (38.3% vs 30.30 average) and less bullish (28.1% vs 38.4 average). Remember, this is a contrary indicator and falls into the category of "Everybody's Never right" so this is actually a bullish sign.

The political situation is helping nobody but the late night comedy shows. They love Trump because he provides so much material. Unfortunately, the rest of us and the world isn't so amused. We are seeing a fractured Republican Party that doesn't seem to be able to do anything that requires solidarity. The way things look now, they may be faced with what the Democrats dealt with in the 2014 midterms where Obama was an impediment to being re-elected.

I also want to point out that the Russell 2000 (use IWM ETF), an index that has little or no foreign exposure has made the fifth bottom since November 2016 in the area of 1345-1355. Using the IWM, we find ourselves on the lower Bollinger Band, just touching the rising 50 day moving average, and is slightly oversold. To me, this warrants a buy. I will include a new position in the new trades section. *CAM*

All trades were based on your participation in the texting service to receive updates.

DATE		PRICE	COST	PROCEEDS	RESULTS
08/25	Bought 8 NVDA Sept 1st 170 Calls	0.92	736		
08/24	Sold 2 M September \$ 20 Calls	1.45		290	210 Gain
08/24	Sold 3 M September \$ 20 Calls	1.01		303	183 Gain
08/25	Sold 1 NVDA August 25th 165 Call	1.78		178	111 Gain
08/24	Sold 1 NVDA August 25th 165 Call	2.50		250	183 Gain
08/23	Sold 1 NVDA August 25th 165 Call	1.80		180	113 Gain
08/23	Sold 1 NVDA August 25th 165 Call	1.80		180	113 Gain
08/23	Sold 2 NVDA August 25th 165 Calls (100% Profit Rule)	1.34		268	134 Gain
08/23	Sold 2 NVDA August 25th 165 Calls (100% Profit Rule)	1.34		268	134 Gain
08/23	Bought 6 CSTM September \$10 Calls	0.80	480		
08/22	Sold 5 M September \$ 20 Calls (100% Profit Rule)	0.80		400	200 Gain
08/21	Bought 8 NVDA August 25th \$165 Calls	0.67	536		
08/21	Bought 10 M September \$20 Calls	0.40	400		
08/08	Bought 8 SKYW Sept \$ 40 Calls	0.30	240		

NEW TRADES OPTIONS ACCOUNT

(1) BUY 4 IWM SEPTEMBER 138 CALLS @ \$ 1.20

NEW TRADES \$ 100 000 ACCOUNT:

(1) BUY 8 IWM SEPTEMBER 138 CALLS @ \$ 1.20

MARKET LABORATORY - WEEKLY CHANGES

Dow 21,813.67 +139.16 +0.64%	Nasdaq 6265.64 +49.12 +0.79%	S&P 500 2443.05 +17.50 +0.72%	Transportation 9133.75 +38.44 +0.42%	Russell 2000 1377.45 +19.66 +1.45%	Nasdaq100 5822.53 +31.62 +0.55%
Gold (spot) 1294.50 +6.20 +0.5%	Silver Sept 17.049 +0.47 +0.3%	Crude Aug 47.87 -0.64 -1.3%	Heating Oil 1.6239 -0.0107 -0.6%	Unleaded Gas 1.5408 + 0.008 +0.5%	Natural Gas 2.9240 -0.0873 -2.9%
VIX 11.28 -2.98 -21.0%	Put/Call Ratios S&P 100 119/100's -25/100's	Put/Call Ratios CBOE Equity 61/100's -10/100's	Bonds 156-17 +0-22 2.95% 0-024%	10 Yr. Note 126-28 +0-3 2.26%-030%	Copper 3.0335 +0.006 +0.2%
CRB Inflation Index 177.83 +0.33 +0.2%	Barron's* Confidence 76.0 +0.8	S&P100 1080.02 +6.50 +0.61%	5 YR Note 118-18 -0+02 1.79%-0.05%	Dollar 92.52 -0.91 -1.0%	DJ Utilities 746.48 +8.10 +1.10%
AAII Confidence Index Average	Bullish 28.1% -6.1% 38.4%	Bearish 38.3% +5.5% 30.30%	Neutral 33.6% +0.6% 30.96%	M1 Money Supply +6.93% Aug 14 th	M2 Money Supply +4.89% Aug 14 th
Pinner		W. II IV. I			

Prices are copied from Barron's Weekly and Yahoo Finance and may be incorrect * Component Change is in the Confidence Index

S	SUPPORT	RESISTANCE
S&P 500 NASDAQ (QQQ)	2417 139.90	2490 144.20
Trans	8950	9260
DOW	21,610	22,110
TLT	124.90	128.80

Each Stock is allocated a theoretical \$5,000 share of the portfolio

	Purchase Price	Purchase Date	Stop/Loss	Price/Date Sold	Profit/(\$ 920Los)
BBRY 400	11.21	06/07			
GLYC 400	12.66	06/01			
HL 500	5.72	06/01			
GSAT 1500	2.30	05/18			
SLV 300	15.78	05/15			
AGQ 150	40.39	04/07			
NUGT 75	35.68	03/13			
RWM 100	50.60	11/21			
SPXU 200	22.88	11/14			
AMBA 100	63.75	10/13			
MOS 200	27.53	05/02			
EYES 500	5.04	04/04			
EYES 1000	6.49	12/28			
TWTR 200	28.51	10/28			
MOS 100	43.55	08/14			
HL 500	3.95	05/03			
SAN 600	8.40	12/16			
TEXQY 200	6.56	7/11			
REPR* 5000	0.22	10/22/12			

Recommendations will be both listed in this letter and texted to members. Previous closed out trades can be seen on each preceding weekly market letter. X means stop loss

Aug 21st;14th;7th;July31st;24th;17th;10th;3rd;June26th;19th;12th;5th;May9th;22rd;15th;8th;1st;Aprilth;24th;17th

SCO means stop close only Additional New Options Trades: will be texted

Large Account: Additional trades and stop losses will be Texted and E-Mailed The new number has been provided. Call Dave Rodgers if there are problems at (832) 236- 3640. Or Mike King 702 650 3000; Charles Moskowitz 617 827 1296

There were several closed out options positions last week gaining \$2,814.00 in options trading. There were no closing stock trades: There are three remaining long option positions, the 15 SKYW September \$40 Calls bought at \$ 0.30 costing \$450.00; the 12 CSTM September \$ 10 Calls bought at \$ 0.80 and 16 NVDA Sept 1st Calls bought at \$ 0.92. The net gain for the week was \$ 2,814.00. The total margin requirement for options is \$ 2,882.00. The options expire on the third Friday of each Month unless otherwise posted. The Stock table has the following 19 positions: AGQ, BBRY,EYES (2), GLYC, GSAT,HL(2), MOS (2), NUGT, REPR, RWM, SAN, SCO,SLV, SPXU TEXQY, TWTR,

The options call for a \$ 2,500 investment unless otherwise stated; each stock position requires \$5,000 unless otherwise mentioned specifically. Money management is based on a hypothetical \$ 100,000.00. The 19 stock positions would cost \$ 79,338.00. The open long options position; the SKYW September \$ 40 Calls require \$ 450.00; the 12 CSTM Calls need \$960, while the requirement for the 16 NVDA Sept 1st 170 Calls is \$1,472.00. The three options trades require \$ 2882.00; when combined with the stock requirement of \$79,338.00 equals \$82,220.00 which leaves excess cash of \$17,780.00.

YEAR TO DATE the \$100,000 Account has had 148 closed out trades between stocks, options and covered writes versus stock positions. There were no closed stock positions last week. There was an improvement in open trade equity (+\$1,451) on the open positions to a minus \$20,294.00. On the former closed positions, 101 were gains and 47 were losses. Gains to date equal \$53,215.00; losses equal \$18,689.00, for a net gain of \$34,526.00. This number does not take into consideration commissions or open gains or losses.

These figures are approximate and there might be errors. The trading is hypothetical and we do not count commission costs.

Previous Week's Recommendations and Rules for the \$ 100,000 account

- Text UPDATES to number provided
- All options count for about \$2,500.00 for model portfolio calculations unless otherwise stated.
- When the option has doubled sell half the position.
- Stop Loss protection is half if Option trades above 50 Cents or offered with each trade.
- The cost of the option is the asking price (or the price between the bid and ask, whichever is more realistic)
- The options will be followed until closed out.
- Option Symbols are stock symbol with expiration month and strike price
- Subscribers can follow us on Twitter or call 702 650 3000 for up to date information.

Note: Closed out stock and option positions can be found in previous weekly market letters: Such as

Aug 21st;14th;7th;July 31st;July 24th;17th;10th; 3rd;June 26th;19th; 12th; 5th; May 29th;22rd;15th;8th; 1st; April 24th; 17th

Option		COST	Date	Sold	Date	Profit/(Loss)
NVDA Sept1st 170 16 lots	<u>Calls</u> 0.92		08/25/17			
NVDA Aug 25 th 165 16 lots	<u>Calls</u> 0.67		08/21/17	1.34 Sold 8 100% profit rule	08/23/2017	\$ 540
				1.80 SOLD 4	08/23/2017	\$ 454 \$ 267
				2.50 SOLD 2 1.78 SOLD2	08/24/2017 08/25/2017	\$ 367 \$ 223
				1.76 SOLD2	00/23/2017	ΨΖΖΟ
M Sept 20 20 lots	<u>Calls</u> 0.40		08/21/17	0.80 sold 10 (100% Profit Rule sold Half)	08/22/2017	\$ 400
				1.45 [°]	08/24/2017	\$ 525
				1.01	08/24/2017	\$ 305
CSTM Sept 10 12 lots	<u>Calls</u> 0.80		08/23/17			
SKYW Sept 40 15 lots	<u>Calls</u> 0.30		08/08/17			

This week's Economic Numbers and Earnings Releases: Before the Open on top of the Row; After the Close below the Economics information and News releases: Space is limited:

MONDAY	Standex International SXI (1.39 vs 1.31)
	08:30 hrs. International Trade in Goods July (-64.6Bln vs -\$ 64,3 Bln 08:30 hrs. Adv. Wholesale Inventories (0.2% vs 0.7%)
	Catalent CTLT (0.57 vs 0.52) Exa EXA (-0.12 vs -0.05) Hill International HIL 0.01 vs 0.03 PAREXEL PRXL (0.93 vs 0.94) Prospect Capital PSEC (0.21 vs 0.26)
TUESDAY	Bank of Montreal BMO (2.00 vs 1.94) Bank of Nova Scotia BNS (1.65 vs 1.54) Best Buy BBY (BBY 0.63 vs 0.57) Fang SFUN (0.02 vs -0.08) Hain Celestial HAIN (0.40)
	09:00 hrs Case-Shiller 20-city Index June (5,7% vs 5.7%) 10:00 hrs Consumer Confidence August (120.3 vs 121.1)
	Caleres CAL (0.45 vs 0.46) H&R Block HRB (-0.62 vs -0.55) NCI Building Systems NCS (0.32 vs 0.33) Ollie's Bargain Outlet OLLI (0.25 vs 0.21) ScanSource SCSC 0.68 vs 0.51
WEDNESDAY	Analog Devices ADI (1.15 vs 0.82) Barnes and Noble Education BNED (-0.59 vs -0.60) Dycom DY (1.44 vs 1.64) ReneSola SOL -0.76 vs 0.05 Yingli Green Energy YGE -2.05
	07:00 hrs. MBA Mortgage Applications Index 08/26 (NA vs -0.5%) 08:15 hrs. ADP Employment Change Aug (180K vs 178K) 08:30 hrs. GDP Second Estimate 2 nd Qtr. (+2.7% vs +2.6%) 08:30 hrs. GDP Deflator- 2 nd Estimate 2 nd (+1.0% vs + 1.0%) 10:30 hrs. Crude Inventories 08/26 (NA vs -3.3Mln)
	Ctrip CTRP (0.19 vs 0.02) Greif GEF (0.85 vs 0.91) Five Below FIVE 0,26 vs 0.18
THURSDAY	Campbell Soup CPB (0.55 vs 0.46) Ciena CIEN (0.49 vs 0.42) Dollar General DG (1.09 vs 1.08) Genesco GCO (-0.07 vs 0.34) Lands' End LE (-0.09 vs -0.06) Leju LEJU (-0.16 vs 0.11) Titan Machinery TITN (-0.01 vs -0.12) Toronto Dominion Bank TD (1.36 vs 1.27)
	07:30 hrs. Challenger Job Cuts Aug (NA vs -37.6%) 08:30 hrs. Initial Claims 08/26 08:30 hrs. Continuing Claims 08/19 08:30 hrs. Personal Income July (0.3% vs 0.0%) 08:30 hrs. Personal Spending July (0.4% vs 0.1%)
	08:30 hrs. PCE Prices-CORE July
	10:00 hrs. Pending Home Sales 10:30 hrs. Natural Gas Inventories) 08/26 (NA vs 43bcf) Ambarella AMBA (0.44 vs 0.54) Cooper COO (2.58 vs 2.30) lululemon LULU 0.35 v 0.38 Palo Alto Networks PANW 0.79 vs 0.50 Restoration Hardware RH (0.47 vs 0.44)
FRIDAY	Big Lots BIG (0.62 vs 0.52)
	08:30 hrs. Nonfarm Payrolls Aug (183K vs 209K) 08:30 hrs. Nonfarm Private Payrolls Aug (173K vs 205K) 08:30 hrs. Unemployment Rate Aug (4.3% vs 4.3%) 08:30 hrs. Average Hourly Earnings Aug (0.2% vs 0.3%) 08:30 hrs. Average Workweek Aug (34.5 vs 34.5) 10:00 ISM Index Aug (56.8 vs 56.3) 10:00 hrs. Construction Spending July (0.5% vs -1.3%) 10:00 hrs. Michigan Sentiment Aug (97.1 vs 97.6)
	The U.S. Oil Rig Count decreased by 4 Rigs to 759. The Nat Gas Rig count increased by 1 to a total of 182, there is one miscellaneous, making a total rig count 946. There are 455 more rigs in operation this year, up from 2016. Crude closed lower at \$48.51.off \$ 0.31 or -0.6%. Natural Gas closed the week falling \$.0873 or -2.9% at \$2.8930.

day moving average at about 134.12, making a double botton rinceton Research Market Strategies Newsletter	n and holding. It then proceeded to rally to Page 7
FUNDAMENTALS The Dow Jones Industrials (21,813.67+139.16 or + 0.64% reb Other indexes also outperformed: The Russell 2000 rebounded 2000 ETF, IWM (137.07+\$2.15 or + 1.6%) led all indexes for the second sec	ed 19.66 points or + 1.45%. The Russell the week after having plummeted to its 200

137.18, breaking above its declining 13-day price moving average. As the historically difficult month of September approaches, many stocks are struggling to hold relatively elevated levels.

The S&P 500 (2425.55) - \$35.51 or-1.4% was another losing index closing with losses of 1.4% for the week, even though after reaching 2480, being overbought and unable to hold its gains, it just hovered sideways and did not trade outside of its Tuesday range which was just 2,433 to 2,455. The market is continuously influenced by fundamental and technical factors and it's never easy to navigate the crosscurrents.

The Nasdaq Composite (6216.53) - \$ 40.03 or -0.6% appears to be in a position to accelerate down in September possibly ending the bull market after gaining 3.4% in July. The QQQ at \$ 142.25 fell \$ 0.98 for the entire month of August holding just above its 50 day moving average, but making life more difficult for the shorts.

The Dow Jones Transportation Average (9095.31) - \$ 103.74 or -1.1% was the second worst performing index last week. It collapsed 352 points after reaching its 50 day price moving average. The Dow Jones Transportation Index Fund reversed (IYT: 163.78) - \$1.62 or 1% after reaching a high of \$170.14. This action would appear to end the bull market. To be convincing it needs to break below the 200 day moving average at about 163.

Index	Started Week	Ended Week	Change	% Change	YTD %
DJIA	21674.15	21813.67	139.52	+0.6%	10.4
Nasdaq	6216.53	6265.64	50.89	0.8%	15.5
S&P 500	2425.55	2443.55	17.50	0.7%	9.1
Russell 2000	1357.13	1377.45	15.32	1.1%	1.6
DJT	9094.31	9133.75	75.62	0.8%	1.4

US Dollar (DXYO: 93.29) -0.14 or -0.15%. The dollar struggled to hold its gains of the previous week just below the 13 day price moving average at 93.44. The weaker greenback is supportive for stocks.

Volatility (VIX: \$11.28 -\$ 2.98 or -20.9%) The Market was steady, stocks were favorable as a result volatility declined, which tends to trade inversely with stocks. The gauge, also known as the VIX, measures options bets on the S&P 500 index.

CBOE OEX Volatility Index (VXO-X 10.32) - \$2.59 or - 20.1%. The index came back down below its 200 day price moving average as stocks rallied. It still remains above the 50 day price moving average.

The UVXY, (\$ 31.23) or - \$7.74 - 24.8%; declined as stocks were strong; The Ultra VIX short term indicator had declined every month through July, since November 2016, but now has possibly stabilized in a seasonal period of turbulence.

The U.S. Oil Fund (USO: \$9.73) -0.24 or-2.4% trying to hold in a congestion area between the 30 and 200 day price moving averages.

Semiconductors (SMH: \$86.30) + \$0.83 or + 1.0%; held steady during firm overall stock markets just above its 50 day moving average.

Gold (GLD: \$122.71+\$ 0.41 or +0.3% Found new support at the \$120.50 level and then rallied impressively to close above all moving averages challenging the year's highs achieved June 7th.

Russell 2000 (IWM: \$ 137.07) + 2.15 or + 1.6%: Rallied above the 13 day moving average after descending down to the critical 200 day price moving average where it found good support.

The GDX, the VanEck Gold Miners ETF (GDX: 23.43) + \$ 0.50 or +2.2% found good support at the declining 200 day price moving average, and its highest close since June 6th.

Alibaba (BABA: \$ 172.60) + **\$5.10** or **+ 3%**. It rebounded nicely from oversold conditions remaining solidly bullish. Our original buy recommendation on April 11th was \$111.00/share.

Amazon (AMZN: \$948.94) -9.53 or -1.0%: Climaxed at \$1083.31 and since dropped 140 points during the past three weeks seeking a new direction.

Crude OIL (\$47.87) -0.64-1.3% The strong world economy is supportive in utilizing huge supplies.

Natural Gas (2.924) -0.0873 U.S. natural gas consumption is at a 2-year low as the result of mild weather. According to the EIA, US natural gas consumption will average 72.6 Bcf per day in 2017 and 75.8 Bcf per day in 2018. Consumption averaged 75.1 Bcf per day in 2016 and 74.7 Bcf per day in 2015. Hedge funds' bullish positions in futures fell for the third straight week suggesting that they are bearish on natural gas.

S&P 500 (SPY: 2448.32) Tuesday's range being the whole range for the entire week



ECONOMICS


July Durable Goods Orders declined 6.8% even worse than the Briefing.com consensus expecting a negative 6.0% number, pressured by a sharp 19.0% drop in transportation equipment orders that was led by a 70.7% decline in nondefense aircraft and parts orders. Excluding transportation, Durable Goods orders rose 0.5%, which was in-line with most consensus estimates.

The upshot of the report was in the shipments and new orders for nondefense capital goods excluding aircraft. Shipments for that component, which factors into GDP computations, increased 1.0% while orders, which are considered a proxy for business spending, increased 0.4%. The key takeaway from the report, then, is that it forecasts a somewhat decent growth news for the manufacturing sector early in the third quarter. New orders for primary metals were unchanged. New orders for fabricated metal products

were up 1.0%; new orders for machinery were down 1.4%; new orders for computers and electronic products increased 1.6%; New orders for electrical equipment, appliances and components increased 2.6%; New orders for all other durable goods increased 0.6%.

Category	JUL	JUN	MAY	APR	MAR
Total Durable Orders	-6.8%	6.4%	0.0%	-0.8%	2.4%
Less Defense	-7.8%	6.4%	0.6%	-0.8%	1.1%
Less Transport	0.5%	0.1%	0.8%	-0.4%	0.9%
Transportation	-19.0%	19.1%	-1.6%	-1.6%	5.4%
Capital Goods	-16.4%	19.5%	-0.9%	-1.9%	4.7%
Nondefense	-20.2%	20.9%	-0.1%	-2.4%	1.9%
Nondefense/non-aircraft (core cap goods)	0.4%	0.0%	0.8%	0.3%	0.0%
Defense Cap Goods	14.7%	9.0%	-6.2%	1.7%	30.6%

Durable Goods Orders y/y%



Source: Census Bureau; updated 08/25/17

Briefing.com

Real GDP for the second quarter was estimated to have increased at a seasonally adjusted annual rate of 2.6% (Briefing.com consensus 2.8%) following a downwardly revised 1.2% increase (from 1.4%) for the first quarter. Real final sales, which exclude the change in private inventories, were also up 2.6%. The largest contributors to the increase in Q2 GDP were personal consumption expenditures 1.93 percentage points, gross private domestic investment,+0.34 percentage points, and net exports +0.18 percentage points.


The GDP Price Deflator was up 1.0% (Briefing.com consensus 1.3%) following an upwardly revised 2.0% increase (from 1.9%) for the first quarter.

The change in private inventories subtracted just 0.02 percentage points from Q2 GDP growth. Government spending added 0.12 percentage points, with federal spending contributing 0.15 percentage points and state and local spending subtracting 0.02 percentage points. Defense spending, which contributed 0.20 percentage points, accounted for the entirety of the positive contribution from federal spending.

In conjunction with the Q2 GDP report, the BEA released annual benchmark revisions for 2014 through the first quarter of 2017. With the revisions, it was said that real GDP from 2013 to 2016 increased at an average annual rate of 2.3% versus 2.2% with the previously published estimates. From the fourth quarter of 2013 to the first quarter of 2017, real GDP increased at an average annual rate of 2.1%, which was unchanged from previously published estimates.

The key takeaway from the Q2 GDP report, then, is that the average for the first half of 2017 was subpar at 1.9%, which should continue to keep any concerns about the prospect of a near-term rate hike from the Fed under wraps.

Category	Q2	Q1	Q4	Q3	Q2
GDP	2.6%	1.2%	1.8%	2.8%	2.2%
Inventories (change)	-\$0.3B	\$1.2B	\$63.1B	\$17.6B	\$12.2B
Final Sales	2.6%	2.7%	0.7%	2.6%	2.9%
PCE	2.8%	1.9%	2.9%	2.8%	3.0%
Nonresidential Inv.	5.2%	7.1%	0.2%	3.4%	3.3%
Structures	4.9%	14.8%	-2.2%	14.3%	0.5%
Equipment	8.2%	4.4%	1.8%	-2.1%	-0.6%
Intellectual Property	1.4%	5.8%	-0.4%	4.2%	11.1%
Residential Inv.	-6.8%	11.1%	7.1%	-4.5%	-4.8%
Net Exports	-\$614.9B	-\$622.2B	-\$631.1B	-\$557.3B	-\$572.4B
Export	4.1%	7.3%	-3.8%	6.4%	2.8%
Imports	2.1%	4.3%	8.1%	2.7%	0.4%
Government	0.7%	-0.6%	0.2%	0.5%	-0.9%
GDP Price Index	1.0%	2.0%	2.0%	1.4%	2.4%



Source: Bureau of Economic Analysis; updated 07/28/17

Briefing.com

Consumer Confidence from The Conference Board increased to 121.1 (Briefing.com consensus 116.8) in July from a downwardly revised 117.3 (from 118.9) in June. The Present Situation Index increased from 143.9 to 147.8, which is a 16-year high. The Expectations Index rose from 99.6 to 103.3.

Despite an improved outlook for the labor market, consumers were not as upbeat, the report said, about their income prospects as in June. The percentage of consumers expecting an improvement in their income declined from 20.9% to 20.0%, while the proportion expecting a decline increased from 9.3% to 10.0%. The key takeaway from the report is that the uptick in July was encouraged by a pickup in sentiment for current conditions as well as the short-term outlook.

Category	JUL	JUN	MAY	APR	MAR
Conference Board	121.1	117.3	117.6	119.4	124.9
Expectations	103.3	99.6	102.3	105.4	112.3
Present Situation	147.8	143.9	140.6	140.3	143.9
Employment ('plentiful' less 'hard to get')	16.1	13.6	11.7	10.9	12.8
1 yr inflation expectations	4.6%	4.6%	4.7%	4.7%	4.7%





CYCLES

The end of August trading, the DJ Transportation Index led all indexes falling below the 13 and 50 day price moving averages all the way down to the 200 day moving average which it threatens to break. S&P 500 had a break below both the 13-day and 50 day price moving averages, possibly setting up further declines to be forthcoming. The 50-day price moving average becomes a major hurdle with resistance at 9420.

Since 1950, September is the worst performing month of the year for DJIA (-0.8%), S&P 500 (-0.5%), NASDAQ (-0.5%) (since 1971), Russell 1000 (-0.6%), and Russell 2000 (-0.5%) (since 1979). September was creamed four years straight from 1999-2002 after four solid years from 1995-1998 during the dot.com bubble madness. In post-election years, September's overall rank improves modestly in post-election years going back to 1953 (second, third or fourth worst month depending on index). Average losses are little changed. Although September 2001 does influence the average declines, the fact remains DJIA and S&P 500 have declined in 9 of the last 16 post-election year Septembers.

	Rank	Avg %	Up	Down
DJIA	9	-0.7	7	9
S&P 500	9	-0.6	7	9
NASDAQ*	10	-0.3	7	4
Russell 1K**	10	-0.7	4	5
Russell 2K**	11	-0.7	6	3
* Since 1973, ** S	ince 1981			

Although the month has opened strong 13 of the last 22 years, that is not likely to occur this year as the rally is behind us. Traders and Fund managers are fearful, and looking for short positions and methods to modify their portfolios to be conservative as the end of the third quarter approaches, causing some nasty selloffs near month-end over the years.

Recent substantial declines occurred following the terrorist attacks in 2001 (Dow: -11.1%) and the collapse of Lehman Brothers in 2008 (Dow: -6.0%). Solid September gains in 2010; DJIA's 7.7%, S&P 500's 8.8% were the best since 1939, but the month suffered nearly the same magnitude declines in 2011, confirming that September can be a volatile month.

September Triple Witching week is generally bullish with S&P 500 advancing twice as many times as declining since 1990, but is has suffered some sizable losses. Triple-Witching Friday was essentially a sure bet for the bulls from 2004 to 2011, but has been a loser four or five of the last five years, depending on index. The week after Triple Witching has been brutal, down 22 of the last 27, averaging an S&P 500 loss of 1.0%. In 2011, DJIA and S&P 500 both lost in excess of 6%.

AUGUST 2017

Sector Seasonalities: Long = (L); Short = (S)

<u>Start:</u> Biotech (L), High-Tech (L), Semiconductor (S)
<u>In Play:</u> Materials (S), Gold & Silver (L), Transports (S), Utilities (L)

Finish: None

MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SAT	SUN	
10112, 3113.8	1	2	3	4	5	6	
		No.		2.00	10000		
	First Trading Day,	First Nine Trading Days of August Are Historically Weak August Worst Dow and S&P Month 1988-2016					
	Dow Down 14 of Last 20						
	Construction Spending						
	ISM Index		5 (C) (MIN)	7509703737777737353			
	Personal Income/Spending		Chain Store Sales	ECRI Future Inflation Index			
	Semiconductor Billings		Factory Orders	Employment Rate			
	Vehicle Sales	10000	ISM Non-Mfg. Index	Int'l Trade Deficit			
7	8	9	10	11	12	13	
	125.000						
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Average August Gains Last 21 Years:					
	Dow: -1.3%	S&P: -1.1%	NAS: -0.6%				
	Up 11 Down 10	Up 11 Down 10	Up 11 Down 10				
	Rank #12	Rank #12	Rank #12				
		Productivity and Costs	PPI				
Consumer Credit		Wholesale Trade	Treasury Budget	CPI			
14	15	16	17	18	19	20	
14	13	10		10	19	20	
Manday of	Mid Augus	st Stronger Than Beginni	ng and End				
Monday of	Mid-Augu						
Expiration Week, Dow Up 15				Expiration Day, Bearish Lately			
of Last 22	Business Inventories			Dow Down 6 of Last 7			
UI Last ZZ	Import/Export Prices		Industrial Production	DOW DOWN 0 OF Last 7			
	NAHB Housing Mrkt Index	FOMC Minutes	Leading Indicators				
	Retail Sales	Housing Starts	Philadelphia Fed Survey	U Mich Consumer Sentiment			
21	22	23	24	25	26	27	
21	22	23	24	23	20	21	
	Week After Augu						
	week After Augu						
		11 - 12 - 12 - 12 - 12 - 12 - 12 - 12 -	0.00	1.1.1.1.1.1.1.1			
	SEMI Book to Bill Ratio	New Home Sales	Existing Home Sales	Durable Goods			
28	29	30	31	413.0 (17.0 (19.0)			
		August's Next-to-Last		*Tuesdays: Weekly Chain S	tore Sales		
		Trading Day,		& Avg Hourly Earnings			
		S&P Down 16		*Wednesdays: Oil & Gas Inv	ventories		
		of Last 21		*Thursdays: Weekly Unemp		rt, Weekly	
			Chain Store Sales	Mutual Fund Flows & Weekly	Natural Gas	Storage Repo	
		Agricultural Prices	Chicago PMI	*Fridays: Weekly Leading Ed	conomic Index	•	
	Consumer Confidence	GDP - Q2 Revised	Personal Income/Spending				
and the same of the same of			fies a favorable day based on	Bear symbol signi	fies an unfavo	orable day	
Economic release dates of			ing 60% or more of the time on	based on the S&P			

Sector Seasonalities: Long = (L); Short = (S) Start: Oil (S) In Play: Biotech (L), High-Tech (L), Semiconductor (S), Utilities (L), Materials (S), Gold & Silver (L), Transports (S) Finish: None MONDAY WEDNESDAY TUESDAY THURSDAY **FRIDAY** SAT SUN 3 1 First Trading Day, S&P Up 13 of Last 22 *Tuesdays: Weekly Chain Store Sales Construction Spending & Avg Hourly Earnings ECRI Future Inflation Index *Wednesdays: Oil & Gas Inventories Employment Rate *Thursdays: Wkly Unemployment Report, Wkly ISM Index Mutual Fund Flows & Weekly Natural Gas Storage Report Semiconductor Billings *Fridays: Weekly Leading Economic Index U Mich Consumer Sentiment *Except holidays Vehicle Sales 6 8 10 September Gains Last 21 Average Labor Day Day After Labor Day, Dow: -0.7% S&P: -0.3% NAS: -0.1% Dow Up 16 of Last 23 (Market Closed) Up 10 Down 11 Up 11 Down 10 Up 12 Down 9 Rank #9 Rank #10 Rank #10 Beige Book Int'l Trade Deficit Consumer Credit Factory Orders ISM Non-Mfg. Index Productivity and Costs Wholesale Trade 11 12 13 14 15 16 17 In Memory Monday of Triple Expiration Week 2001, Dow Lost 1370 Points (14.3%), Witching Week, 2nd Worst Weekly Point Loss Ever, 5th Worst Week Overall Triple Witching Day, Russell 2000 Down Dow Up 10 of Last 15 11 of Last 18 Business Inventories Industrial Production Retail Sales Treasury Budget U Mich Consumer Sentimen 18 20 21 22 24 19 23 Rosh Hashanah End of September Prone to Weakness From End-of-Q3 Institutional Portfolio Restructuring Week After September Triple Witching Dow Down 21 of Last 27 Average Loss Since 1990, 1.1% SEMI Book to Bill Ratio Housing Starts Existing Home Sales Leading Indicators FOMC Meeting NAHB Housing Mrkt Index Import/Export Prices Philadelphia Fed Surve 25 26 27 28 29 30 1 Last Day of Q3 Dow Down 14 of Last 20 Yom **Kippur** Chicago PMI Consumer Confidence Agricultural Prices Personal Income/Spending GDP - Q2 Final U Mich Consumer Sentiment New Home Sales Durable Goods Bull symbol signifies a favorable day based on the S&P 500 Rising 60% or more of the time on Bear symbol signifies an unfavorable day based on the S&P 500 Falling 60% or more of Economic release dates obtained from sources believed

a particular trading day 1996-2016

to be reliable. All dates subject to change.

the time on a particular trading day 1996-2016

Lower Capitalized Companies with Great Potential

RMS Medical Products (REPR: \$ 0.43)

RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and the latest Freedom Edge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com.

RMS" or the "Company" is pleased to announce the launch of the RMS Freedom Flow Rate Calculator Smart Phone App (available for Android, and iOS). This App is designed to allow customers to more easily configure an RMS infusion system based on the drug being delivered. The App is an easy to use but highly complex calculator which will aid pharmacists, doctors and nurses in determining the proper RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™ to be used with either the FREEDOM60® or the FreedomEdge® Syringe Driver Infusion Systems. Nurses and Pharmacists often make critical decisions about flow rates/tubing and needle selections (size and number of needles to be used for infusion) in order to meet drug delivery protocols and patient desires for time of infusions. This new App will make it very easy to help the patient receive the best care possible.

This RMS Freedom Flow Rate Calculator Smart Phone App was developed for RMS with resources from ContraCare GmbH, a leader in Germany for Contract Management (reimbursement) Services and Managed Care (homecare) solutions. The App is now available for iOS in the Apple™ Store and Android in the Google™ Play store. Just go to your favorite store and type in RMS Freedom and you will be able to find and download this free user friendly app.

Torsten Kühn, Chief Executive Officer of ContraCare, commented "as a premium service provider in Germany's health care system, we aim to partner with leading suppliers to provide the best drugs, medical devices and services to our patients while keeping an eye on the cost efficiency of the treatments we provide. The RMS FREEDOM60® system with its durable and reliable syringe driver and high-quality HIgH-Flo™ subcutaneous safety needle sets are exactly the products we needed for immunoglobulin, antibiotic and many other therapies we are providing today. We are glad that the umbrella organization of Germany's public health insurance confirms the unmet need by approving the RMS FREEDOM60® System for reimbursement."

Eric Bauer, Chief Operating Officer of RMS commented, "It can take 12 to 14 months to obtain country registration; by partnering with a leading health care provider, that time was cut significantly. Contra Care is an exceptional partner and we could not be more pleased with our relationship. Germany is going to be a great market for our high quality products and our ever expanding product line. RMS continues to be the Global industry leader and create exceptional partnerships around the world to improve patient quality of life."

Contra Care GmbH, based in Nuremberg, Germany, is specialized in providing Contract Management (reimbursement) Services and managed Care (homecare) solutions for patients with chronic diseases. The company is certificated in accordance with ISO 9001, ISO 27001, ISO13485 and licensed as a homecare provider of medical devices and treatment services according to German Social Law (SGB).

Enzo Biochem (ENZ: \$ 10.78) - \$.28 or - 2.5%:

Enzo Biochem closed the calendar year 2016 at \$6.94 a share. For the year of 2017, it is up 55.3% versus the Dow Jones +9.7%. Enzo's balance sheet closed their first quarter October 31 with \$67 million in cash and current equivalents and complete elimination of debt. Both the Clinical Lab and Life Science divisions ended the year profitably. New products were added to their catalog and litigations have moved ahead leaving them as a plaintiff with 6 lawsuits in the Delaware Court and one in the

Manhattan Court. Enzo Biochem closed today, June 30, at \$11.04. For the quarter it was up 31.9% and for the first half it was up. 59.08%. The Standard and Poor 500 closed at 2,423 up 2.57% for the quarter and 8.24% for the first half. The stock has been acting great and I hope it continues for the second half of the year.

A quick rundown of the year so far: The Company announced its fiscal 3rd quarter a few weeks ago. For the first time in many years they showed a breakeven third quarter and no cash burn. They actually increased the cash position by \$200,000. I see no reason that this performance will not continue for the rest of the year.

Three new AmpiProbe products were announced as being approved by the New York Department of Health with more approvals anticipated over the near future. As was announced in the conference call on June 11th; the Company anticipates a product rollout to the market in early fall. They will expand their market to include New England and the Atlantic States.

With Enzo now being included by Cigna for reimbursement I would expect to start seeing the top line numbers for Revenues ramp up. The Company also hopes to have blanket approval in all states by the end of the year. In the 2nd quarter conference call a question was asked by the Rodman Renshaw analyst about Alequel for treatment of Crohn's disease. The response by Mr. Weiner was that there are discussions with Hadassah Hospital where the trials were held a few years ago. Crohn's and Uveitis are not in the stock price and if any news comes out on either of these products I feel it would have a very positive effect on the price of the stock.

The stock should consolidate its gains over the near term and as product approvals come in and AmpiProbe moves into the market, the stock price could move to \$15. Positive news on the Therapeutics could move it much higher. There is very little stock available Institutional ownership is stated to be 61.47% and the Officers, Directors and insiders would be an additional 15% to total 76% of the 46 million shares or 35 million shares leaving 11 million in the float. Enzo's market cap is now over \$500 million which will make more Institutions that have a minimum market cap of \$500 million to be buyers of a stock. Barring any unforeseen events I think we should have a very good second half of the year.

Updates on Delaware Litigation

The last earnings report showed a cash position in excess of \$65 million with no debt to speak of and a positive cash flow from their operating divisions. The only cash burn is coming from Litigation expenses and a bit from Research and Development. Litigation in Delaware is on a contingency basis as such Enzo is not on the hook for billable hours. To my knowledge there are 6 suits left after 6 have settled. When the company passed the \$500 million dollar market cap when the stock price reached (\$10.63) they qualified for those Institutions that can't buy microcap stocks. A significant number of Institutions will look to be buyers and with only 47 million shares issued and Institutions already owning 50% and insiders owning 15% that leaves less than 17 million shares in the float.

Pressure Bio Sciences OTCQB: PBIO 4.35*

Recently announced the signing of a new CFO Mr. Joseph L. Damasio Jr. Mr. Damasio has over 20 years of finance and accounting experience most recently as Finance Director at Nelipak Packaging, a private equity backed medical packaging manufacturer with over \$ 100 million in global annual sales. Before joining Nelipak, Mr. Damasio held financial positions at CP Bourg, IQEKC, and Kopin Corporation. Mr Damasio was employed by Pressure BioSciences as both accounting manager (2007) and controller (2008) and finally as Vice President of Finance and Administration (2011).

The hiring of Mr Damasio will allow the Company's CEO Mr Richard T Schumacher, who has been the company's interim CFO for the past two years, and who has been a successful serial life sciences entrepreneur with three successful publicly traded companies to his credit, time to focus on critical operational issues in 2017. Some issues to be attended to include a pending up-list to NASDAQ and their stated goal to build a field sales team this year.

PBIO Develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions. To date, they have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders.

NEEDS IN MEDICINE: In the world of medicine our dramatically improved ability for early detection or to confirm and refine diagnosis ranging from over a hundred types of cancer to tuberculosis and a hundred other maladies and conditions is "bottlenecked" by 30 year old methods of preparing test samples. Collectively such diagnostic samples exceed a hundred million annually.

NEEDS IN RESEARCH: Globally there are over a half a million medical and pharmaceutical research scientists working in over eighty thousand laboratories who are hampered by the time consuming and outdated methods of preparing test samples.

NEEDS IN FORENSICS: Globally, in millions of cases, swift and sure exoneration of the innocent and / or justice for the guilty is often delayed or even denied because of the ponderous means of preparing and conducting DNA and other forensic testing.

PBIO is focused on solving the challenges of biological sample preparation, a crucial laboratory step performed globally by the biological life sciences research scientists. Sample preparation refers to a wide range of activities that precede most forms of scientific analysis. It is often complex, time-consuming and, in our opinion, one of the most error-prone steps of scientific research. Sample preparation is a ubiquitous laboratory undertaking - the requirements of which drive a large and growing worldwide market. PBIO has developed and patented a novel, enabling technology platform that can control the sample preparation process while improving both efficacy and quality. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called **pressure cycling technology, or PCT**, uses alternating cycles of hydrostatic pressure between ambient (normal atmosphere) and ultra-high levels i.e., 35,000 pounds per square inch ("psi") or greater to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.


The PBIO pressure cycling technology uses proprietary and internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid ("DNA"), ribonucleic acid ("RNA"), proteins, lipids and small molecules. Their laboratory instrument, the Barocycler®, and their internally developed consumables product line, which include Pressure Used to Lyse Samples for Extraction ("PULSE") tubes, and other processing tubes, and application specific kits such as consumable products and reagents, together make up their PCT Sample Preparation System ("PCT SPS").

The PBIO pressure cycling technology takes a unique approach that has the potential for broad use in a number of established and emerging life sciences areas, which include:

- Biological sample preparation in potentially thousands of research laboratories worldwide working in human, animal, plant, and microbial diseases and disorders - including but not limited to sample extraction, homogenization, and digestion in genomic, proteomic, lipidomic, metabolomic and small molecule study areas;
 - Pathogen inactivation (useful in vaccine development, infectious disease research, and more);
 - Protein purification, and in the control of chemical reactions, particularly enzymatic (useful in drug design and development);
 - •and immunodiagnostics (useful in the development and detection of biomarkers).

INTELLECTUAL PROPERTY

PBIO has secured their technology through fourteen issued United States patents and ten issued foreign patents covering multiple applications of pressure cycling technology in the life sciences field. They also have additional patents pending. Research indicates that Pressure Bio Science, Inc. is the only company globally to have patents in this new science sector.



Leo Motors (LEOM: \$0.15)* is the premier company that develops electric vehicles (EV's) that can travel at higher speed along roads and freeways. After 10 years of field tests, the Company has surpassed obstacles of speed, torque and reliability over other e-vehicles. Leo motors has developed an array of

electric vehicles and boats, including armored military vehicles, sports cars, utility trucks, passenger buses and electronic title water boats.

Leo Motors primary division, LGM, is producing and marketing electric boats (E- boats). LGM is the one of the few companies in the world that produces a safe high power electric boat. March 2017, LGM unveiled their proprietary new electric powerboat propulsion system at the 2017 Busan Boat Show in Korea. The new LGM powerboat electric propulsion system produces up to 660 horse power (HP) and is compatible with most power boats and yachts.

LGM's electric inboard and outboard propulsion systems now range from 40 HP to 700 HP and also includes their Sailing Generation System that uses wind to recharge batteries while under way, eliminating conventional charging processes. LGM is communicating with potential partners in America for their conversion enterprise.

LGM will enter into the U.S. market this year providing electric conversion services. LGM will replace old internal combustion engine yachts and powerboats to the LGM electric power system.

Smart E-Vehicle Technology

LEO's proprietary electronic vehicle ecosystem has intelligent software which controls a cloud system. LEO developed the Vehicle to Everything (V2E) platform which uses smart technology to manage a cloud in the operating system (OS). The integrated OS allows connectivity with a smart device for improved driving solutions. The smart applications help reduce battery exchange recharge time, and provides roadside assistance. A GPS application uses satellite and mobile networks connected to Android systems using a Bluetooth®. The app sends updates, battery status and swap service information.

Skinvisible (SKVI: \$ 0.025)* Skinvisible Pharmaceuticals, Inc., is a pharmaceutical technology company that has developed over 40 topical prescription (Rx), over-the-counter (OTC) and cosmeceutical products using its patented Invisicare® polymer delivery systems. Invisicare and its products are protected by fourteen patents worldwide. Skinvisible licenses these products to global pharmaceutical, cosmetic and consumer goods companies.

SKINVISIBLE ENTERS THE CANNABIS MARKET

The cannabis market that Skinvisible has entered is vast and one of the fastest growing markets. The legal marijuana industry (medical and recreational) in the USA has reached over \$6 billion in annual sales and is expected to increase to over \$20 billion by 2020. Canada is projected to reach up to \$22 billion annually as it has passed both medical and recreational marijuana laws this past year. Skinvisible is perfectly poised to be a part of this expanding market. It is part of the ancillary cannabis market as Skinvisible does not sell or touch cannabis; it sells its proprietary Invisicare polymers coupled with proven product formulations and services to its licensees. Skinvisible will help bring science-based, patent protected products into this emerging industry. The Company has developed topical and transdermal cannabis products from hemp-derived CBD; with its next developments to include cannabinoids from marijuana (CBD and THC).

SKINVISIBLE RECEIVES FIRST ORDER FOR CHINA

The Company just recently announced that it has completed its first international sale of DermSafe® hand sanitizer through its agent InterSpace Global, Inc. ("InterSpace"). InterSpace is an exporter of "made in USA" products with offices in Salt Lake City, Utah and Shenzhen, China. InterSpace has completed its first sale of DermSafe® with a direct sales company in Shanghai, China. Skinvisible

management attended the launch of DermSafe in Shanghai, China, with 1200+ distributors in attendance. China with a population of over 1.4 billion people is one of the fastest growing economies in the world and represents a huge market for Skinvisible products, not only for DermSafe hand sanitizer but also the OTC line of products including anti-aging skincare line.

NightFood, Inc. (NGTF. 24)* has healthy night-time food specially formulated for nighttime snackers. The Company has an exclusive agreement with RFI, natural ingredient manufacturer and proprietor of Chocamine, a patented cocoa extract which helps with cravings and mood (calmness), and promotes feelings of satiety.

Americans keep gaining more weight. People have the tendency to grab for goodies at the end of the evening as they relax to enjoy some T.V. Eating and snacking too late at night is a contributing factor to gaining weight. Seventy percent of adults, ages 18-54, snack in the hour or two before bed. Chocamine delivers the health benefits of chocolate to the body (amino acids, minerals and polyphenols) without the added sugars, caffeine or fat. People give in to the intense hunger cravings that leads to the consumption of sugary, salty or calorie dense foods to satisfy their appetite and cravings. Most of the snacks that people typically eat can impair sleep, causing a person to wake up feeling unrested. Night Food offers better-for-you alternatives to high-calorie and sleep disruptive junk foods.

The company product line currently includes snack bars in two flavors, either Cookies and Dreams or Midnight Chocolate Crunch. The company recently reported that it is looking into expanding the number of flavors in the Night Food bar line, and also manufacturing products in different snack formats, like ice cream or "bites" Consumers spend over \$50 billion/year on night-time snacks...over \$1B every week. In general, snacking trends have shifted much healthier over the past several years, but industry research continues to show that the least healthy choices of the day occur as we get closer to bedtime. In fact, the four most popular nighttime snack categories, in order, are salty snacks (chips, pretzels, popcorn), ice cream, chocolate candy, and cookies, Management believes that, just as there are energy versions of many popular foods (energy jerky, energy candy, energy waffles, energy gum, energy chips, energy bars), foods can also be formulated to be more nighttime appropriate and sleep-friendly.

We've seen it happen with low-carb, we've seen it happen with gluten-free.

Fundamental Analysis: Stocks To Buy with Stops: Using fundamentals the following are stocks to trade hypothetically. They have done well. We have taken numerous profits as indicated on the table below. In addition many have been stopped out with small losses. As indicated on the table below, balance is critical. And we have exited most long positions. Alibaba and Boeing have made a great deal of points. We are taking profits. We have no position in Alcoa AA. If long, raise stops to \$ 35 as a risk point. Flushing Financial FFIC fell below the 50 day price moving average on March 3rd, and again on August 9th and now has even breached the 200 day m.a. We have sold the Flushing Financial as indicated on the table. We have been looking for a place to buy Bristol Myers. Hecla Mining might be a speculative buy at a double bottom from July 7th at about \$ 4.82-86. We took profits on ENZ but still want to be long at lower prices. The HDGE is long now on our table. We have been patient waiting for the opportunity. It catapulted above its 50 day price moving average and is relevant at this time. It is a decent long or offset against portfolio positions.

	Name	Business Description	PE	P/S	MV mln	Current Price	Buy or Sell Limit	Stop Loss Or offset
BABA	Alibaba	Largest on-line book seller in China; more of a retailer than Amazon	50.67	13.21	275.5B	172.60	Bought @ \$ 111 on 4/7/17 opening	Profits taken 160 -170
AMZN	Amazon	Catalog & Mail Order	189	2.90	394B	948.94 stopped out	Sold on stop 976	No position See July mkt letters
SIMO	Silicon Motion	Semiconductor solutions for mobile storage and	9.7	2.5	1.39B	43.12 Stopped	Bought 39.10	49.40x on June 29 th

		communications				out 49.40	01/28/17	
CIO	City Office REIT	Real Estate Investment Trust high quality Offices	292	5.8	396MIn	12.51	Re Bought at 12.12	11.50x
TPC	Tutor Perini	Construction	12	0.25	1.3B	24.55 Stopped out28.9 0 05/04	19.40 10/31/16	Looking for place to re-buy
BMY	Bristol Myers	Biopharmaceutical Products	28	5.1	94.9B	58.49 No position	Looking to go much higher	If bought sell at 53.90x
ВА	Boeing	Aerospace, commercial jetliners, military systems	14	0.85	81B	236.54	Long at 132 10/04/16	210x
HL	Hecla Mining	Basic Materials	44	3.61	1.7B	5.03 Look for re-entry lower	No Position	A troubled long
FFIC	Flushing Financial	Bank Holding company Savings and loans	13	3.5	592Mln	27.47	19.10 bought 06/27/16	50 day m.a. at 27.45; sell belowj
HDG E	Bear ETF	Seems to stabilize at the \$8.50 level	NA	NA	176.8MI n	8.71	long 8.54 8/03/17	8.54x
AA	Alcoa	Aluminum Processing and Technology	N/A	0.4	9.5B	41.26	21.15 originally bought 2/8/16	\$ If long use \$ 37 stop
ENZ	Enzo Biochem	Life Sciences	NA	1.35	134M	11.05	Bought at 5.13 10/7/16	Sold on Opening Monday 4/3/17 Sold 8.43
BAC	Bank of America	Commercial Bank	10	2.02	165.3B	23.86	Bought at 15.42 9/30/16	23.60x stopped 3/21/17

Mike King Princeton Research 3887 Pacific Street, Las Vegas, Nevada 89121 Or: Charles Moskowitz CAM@MoneyInfo-LLC.com 617 827 1296

Phone: (702) 650-3000 Cell: (702) 493-3683

<u>mike@princetonresearch.com</u> or cam@princetonresearch.com Visit: <u>www.princetonresearch.com</u>

Disclaimer* Princeton is paid \$ 1,500 per month from RMS Medical Products. The SITS contract calls for \$ 1,500 per month. Princeton had been engaged by Target Energy. No contract is currently in place. Princeton is paid \$ 2500 per month by Pressure Biosciences. Princeton was paid about 300,000 restricted shares of Leo Motors. Princeton is paid \$ 2,500 per month for International Star. Princeton is paid \$ 2,500 from Leo Motors. Pursuant to the provisions of Rule 206 (4) of the Investment Advisers Act of 1940, readers should recognize that not all recommendations made in the future will be profitable or will equal the performance of any recommendations referred to in this Email issue. Princeton may buy or sell its free-trading shares in companies it represents at any time. Y means the writer has a position of 10,000 shares in the stock recommended.

UNSUBSCRIBE

To unsubscribe from this newsletter, please reply to this email with UNSUBSCRIBE in the subject line. We will send you a confirmation upon completing your request.